Abstract
Within the last 20 years, several major therapeutic advances have markedly improved the prognosis of patients with coronary artery disease (CAD). Among these drugs, two of them [angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers] have demonstrated their beneficial effects in hypertensive patients. In addition, ACE inhibitors and particularly perindopril have shown a strong benefit in terms of secondary prevention in patients with stable CAD. Within the last 2 years, it has been shown that the simultaneous prescription of these drugs may reinforce their action and a synergistic effect might be observed. This paper reports a post hoc analysis of the EUROPA trial suggesting a clinical synergy of perindopril and calcium channel blockers in these particular patients. There was a significant relative risk reduction of the primary end point on combination perindopril/calcium channel blockers when compared with calcium channel blockers alone.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
